Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease.

Szczegóły
Abstrakt

Tytuł:: Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease.
Autorzy:: Mengel D; Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.; Department of Neurodegenerative Diseases, Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Janelidze S; Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Glynn RJ; Division of Preventive Medicine, Brigham & Women's Hospital, Boston, MA, USA.
Liu W; Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Hansson O; Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.; Memory Clinic, Skåne University Hospital, Malmö, Sweden.
Walsh DM; Laboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Źródło:: Annals of neurology [Ann Neurol] 2020 Nov; Vol. 88 (5), pp. 878-892. Date of Electronic Publication: 2020 Sep 25.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: New York, NY : Wiley-Liss
Original Publication: Boston, Little, Brown.
MeSH Terms:: Genetic Markers*
Alzheimer Disease/*blood
Biomarkers/*blood
tau Proteins/*blood
Age of Onset ; Aged ; Alzheimer Disease/cerebrospinal fluid ; Biomarkers/cerebrospinal fluid ; Cognitive Dysfunction/blood ; Cognitive Dysfunction/genetics ; Cohort Studies ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Neurodegenerative Diseases/blood ; Neurodegenerative Diseases/genetics ; Neurofilament Proteins/blood ; tau Proteins/cerebrospinal fluid ; tau Proteins/genetics
References:: Walsh DM, Selkoe DJ. Amyloid β-protein and beyond: the path forward in Alzheimer's disease. Curr Opin Neurobiol 2020;61:116-124.
Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med 2020;26:379-386.
Mayeux R, Schupf N. Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants. Neurobiol Aging 2011;32:S10-S19.
Olsson B, Blennow K, Zetterberg H. The clinical value of fluid biomarkers for dementia diagnosis - Authors' reply. Lancet Neurol 2016;15:1204-1205.
Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science 2015;347:1260419.
Roher AE, Esh CL, Kokjohn TA, et al. Amyloid β peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 2009;5:18-29.
Henriksen K, O'Bryant SE, Hampel H, et al. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 2014;10:115-131.
Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 2016;15:673-684.
Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-413.
Johnson GV, Seubert P, Cox TM, et al. The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. J Neurochem 1997;68:430-433.
Meredith JE Jr, Sankaranarayanan S, Guss V, et al. Characterization of novel CSF tau and ptau biomarkers for Alzheimer's disease. PLoS One 2013;8:e76523.
Kanmert D, Cantlon A, Muratore CR, et al. C-terminally truncated forms of tau, but not full-length tau or its C-terminal fragments, are released from neurons independently of cell death. J Neurosci 2015;35:10851-10865.
Sato C, Barthelemy NR, Mawuenyega KG, et al. Tau kinetics in neurons and the human central nervous system. Neuron 2018;97:1284-1298.
Ashton NJ, Hye A, Rajkumar AP, et al. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol 2020;16:265-284.
Neselius S, Zetterberg H, Blennow K, et al. Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. Brain Inj 2013;27:425-433.
Chiu MJ, Chen YF, Chen TF, et al. Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease. Hum Brain Mapp 2014;35:3132-3142.
Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther 2013;5:9.
Dage JL, Wennberg AMV, Airey DC, et al. Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement 2016;12:1226-1234.
Mattsson N, Zetterberg H, Janelidze S, et al. Plasma tau in Alzheimer disease. Neurology 2016;87:1827-1835.
Yanamandra K, Patel TK, Jiang H, et al. Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci Transl Med 2017;9:eaal2029.
Kasai T, Tatebe H, Kondo M, et al. Increased levels of plasma total tau in adult down syndrome. PLoS One 2017;12:e0188802.
Chiu MJ, Yang SY, Horng HE, et al. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease. ACS Chem Nerosci 2013;4:1530-1536.
Mielke MM, Hagen CE, Wennberg AMV, et al. Association of Plasma Total tau Level with Cognitive Decline and Risk of mild cognitive impairment or dementia in the Mayo Clinic study on aging. JAMA Neurol 2017;74:1073-1080.
de Wolf F, Ghanbari M, Licher S, et al. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia: a population based study. Brain 2020;143:1220-1232.
Deters KD, Risacher SL, Kim S, et al. Plasma tau association with brain atrophy in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2017;58:1245-1254.
Chen J, Yu JT, Wojta K, et al. Genome-wide association study identifies MAPT locus influencing human plasma tau levels. Neurology 2017;88:669-676.
Palmqvist S, Janelidze S, Stomrud E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol 2019;76:1060.
Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 2020;19:422-433.
Tatebe H, Kasai T, Ohmichi T, et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. Mol Neurodegen 2017;12:63.
Barthelemy NR, Gabelle A, Hirtz C, et al. Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer's disease, progressive Supranuclear palsy, and dementia with Lewy bodies. J Alzheimers Dis 2016;51:1033-1043.
Chen Z, Mengel D, Keshavan A, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. Alzheimers Dement 2019;15:487-496.
Cicognola C, Brinkmalm G, Wahlgren J, et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. Acta Neuropathol 2019;137:279-296.
Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577-589.
Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of Plasma Neurofilament Light with Neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2017;74:557-566.
Lewczuk P, Ermann N, Andreasson U, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimers Res Ther 2018;10:71.
Mattsson N, Insel PS, Palmqvist S, et al. Increased amyloidogenic APP processing in APOE ε4-negative individuals with cerebral beta-amyloidosis. Nat Commun 2016;7:10918.
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology 1993;43:250-260.
Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 2005;20:S11-S20.
Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid Aβ42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014;71:1282-1289.
Mengel D, Liu W, Glynn RJ, et al. Dynamics of plasma biomarkers in down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase. Alzheimers Res Ther 2020;12:27.
Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement 2019;11:730-743.
Lin YS, Lee WJ, Wang SJ, Fuh JL. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep 2018;8:17368.
Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer's disease. Mol Brain 2019;12:26.
Matias-Guiu JA, Gomez-Pinedo U, Forero L, et al. Plasma Neurofilament light chain in primary progressive aphasia and related disorders: clinical significance and metabolic correlates. J Alzheimers Dis 2019;72:773-782.
Sejbaek T, Nielsen HH, Penner N, et al. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients. J Neurol Neurosurg Psychiatry 2019;90:1324-1330.
Staffaroni AM, Kramer AO, Casey M, et al. Association of Blood and Cerebrospinal Fluid tau Level and other biomarkers with survival time in sporadic Creutzfeldt-Jakob disease. JAMA Neurol 2019;76:969.
Gaetani L, Blennow K, Calabresi P, et al. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 2019;90:870-881.
Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement 2018;14:989-997.
Palmqvist S, Insel PS, Stomrud E, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Mol Med 2019;11:e11170.
Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med 2020;26:387-397.
Substance Nomenclature:: 0 (Biomarkers)
0 (Genetic Markers)
0 (MAPT protein, human)
0 (Neurofilament Proteins)
0 (tau Proteins)
Entry Date(s):: Date Created: 20200824 Date Completed: 20201214 Latest Revision: 20201214
Update Code:: 20240105
DOI:: 10.1002/ana.25885
PMID:: 32829532
: Czasopismo naukowe

Full Text Finder

Objective: There is an urgent need for sensitive, widely available, blood-based screening tests to identify presymptomatic individuals destined to develop Alzheimer's disease (AD). We investigated whether tau detected in plasma by our in-house NT1 assay is specifically altered in AD, and when applied to patients with subjective cognitive decline (SCD) or mild cognitive impairment (MCI) can serve to predict progression to AD dementia. The predictive value of NT1 versus tau measured using assays from Quanterix and Roche, and the specificity of NT1 for AD versus a nonspecific marker of neurodegeneration (neurofilament light [NfL]) were also examined.
Methods: NT1 tau and NfL were measured in plasma from prospectively followed patients with SCD or MCI who remained cognitively stable, converted to AD dementia, or converted to non-AD dementias, and in cognitively unimpaired participants. Tau was measured using Quanterix and Roche assays in baseline subjects with SCD and MCI.
Results: Plasma NT1 tau was specifically elevated in AD, but not in non-AD dementia compared with controls, whereas NfL was increased in both AD and non-AD dementias. Baseline specimens from individuals who had SCD or MCI revealed that NT1 tau, but not tau measured using Quanterix or Roche assays, is elevated in subjects who progress to AD dementia. As expected, baseline plasma NfL is elevated in those who progress to AD and non-AD dementias.
Interpretation: Plasma NT1 tau is a specific marker of AD, which is elevated early in disease and may prove useful as a first round screen to identify individuals at risk of developing AD. ANN NEUROL 2020;88:878-892.
(© 2020 American Neurological Association.)

Informacja